Adaptimmune Therapeutics and patients waiting for synovial sarcoma treatment witnessed a historic moment at the start of this month. After over ten years without new synovial sarcoma treatments, a groundbreaking, first-in-class cell therapy, TECELRA (afamitresgene autoleucel) has been approved by the FDA.
This also marks the first approval for the 16-year-old company Adaptimmune Therapeutics, which has gained and lost partnerships with major pharmaceutical companies such as GSK, Astellas, and most recently Roche. These companies were initially interested in Adaptimmune’s distinctive engineered T-cell receptor (TCR) platform, which allows for the modification of T-c...
